How Fairmount’s Paragon incubator steered two more companies to NASDAQ

Two more reverse mergers proposed this week will set up spinouts from Fairmount’s Paragon incubator to become NASDAQ-traded companies, bringing the total to five public companies emerging from the organization.

Fairmount is also co-leading syndicates pouring a total of $500 million into Jade Biosciences Inc. and Crescent Biopharma Inc. as they merge with Aerovate Therapeutics Inc. (NASDAQ:AVTE) and GlycoMimetics Inc. (NASDAQ:GLYC), respectively. Assuming both deals are completed, Paragon will have brought five companies to NASDAQ since mid-2023, including four via reverse merger...